Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial | Neuro-oncology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Patchell RA. The management of brain metastases.  Cancer Treat Rev. 2003;29:533-54014585263Google ScholarCrossref
Bradley KA, Mehta MP. Management of brain metastases.  Semin Oncol. 2004;31:693-70115497123Google ScholarCrossref
Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases.  Int J Radiat Oncol Biol Phys. 1999;45:427-43410487566Google ScholarCrossref
Andrews DW, Scott CB, Sperduto PW.  et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.  Lancet. 2004;363:1665-167215158627Google ScholarCrossref
DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases.  Neurology. 1989;39:789-7962725874Google ScholarCrossref
Patchell RA, Tibbs PA, Regine WF.  et al.  Postoperative radiotherapy in the treatment of single metastases to the brain.  JAMA. 1998;280:1485-14899809728Google ScholarCrossref
Sneed PK, Suh JH, Goetsch SJ.  et al.  A multi-institutional review of radiosurgery alone vs radiosurgery with whole brain radiotherapy as the initial management of brain metastases.  Int J Radiat Oncol Biol Phys. 2002;53:519-52612062592Google ScholarCrossref
Flickinger JC, Kondziolka D, Lunsford LD.  et al.  A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis.  Int J Radiat Oncol Biol Phys. 1994;28:797-8028138431Google ScholarCrossref
Regine WF, Huhn JL, Patchell RA.  et al.  Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications.  Int J Radiat Oncol Biol Phys. 2002;52:333-33811872278Google ScholarCrossref
Pirzkall A, Debus J, Lohr F.  et al.  Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases.  J Clin Oncol. 1998;16:3563-35699817276Google Scholar
Aoyama H, Shirato H, Onimaru R.  et al.  Hypofractionated stereotactic radiotherapy alone without whole brain irradiation for patients with solitary and oligo brain metastasis using non-invasive fixation of the skull.  Int J Radiat Oncol Biol Phys. 2003;56:793-80012788187Google ScholarCrossref
Chidel MA, Suh JH, Reddy CA, Chao ST, Lundbeck MF, Barnett GH. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.  Int J Radiat Oncol Biol Phys. 2000;47:993-99910863070Google ScholarCrossref
Shirato H, Takamura A, Tomita M.  et al.  Stereotactic irradiation without whole-brain irradiation for single brain metastasis.  Int J Radiat Oncol Biol Phys. 1997;37:385-3919069311Google ScholarCrossref
Shaw E, Scott C, Souhami L.  et al.  Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of Radiation Therapy Oncology Group protocol (90-05).  Int J Radiat Oncol Biol Phys. 1996;34:647-6548621289Google ScholarCrossref
Joseph J, Adler JR, Cox RS, Hancock SL. Linear accelerator-based stereotaxic radiosurgery for brain metastases: the influence of number of lesions on survival.  J Clin Oncol. 1996;14:1085-10928648361Google Scholar
Trotti A, Byhardt R, Stetz J.  et al.  Common Toxicity Criteria version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.  Int J Radiat Oncol Biol Phys. 2000;47:13-4710758303Google ScholarCrossref
Gaspar L, Scott C, Rotman M.  et al.  Recursive partition analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.  Int J Radiat Oncol Biol Phys. 1997;37:745-7519128946Google ScholarCrossref
Radiation Therapy Oncology Group.  RTOG/EORTC late radiation morbidity scoring schema. Accessed June 15, 1999
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.  J Am Stat Assoc. 1958;53:457-481Google ScholarCrossref
Cox D. Regression models and life tables.  J R Stat Soc [Ser A]. 1972;34:187-220Google Scholar
Leksell L. The stereotaxic method and radiosurgery of the brain.  Acta Chir Scand. 1951;102:316-31914914373Google Scholar
Patchell RA, Tibbs PA, Walsh JW.  et al.  A randomized trial of surgery in the treatment of single metastases to the brain.  N Engl J Med. 1990;322:494-5002405271Google ScholarCrossref
Mintz AH, Kestle J, Rathbone MP.  et al.  A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single cerebral metastasis.  Cancer. 1996;78:1470-14768839553Google ScholarCrossref
Vecht CJ, Haaxma-Reiche H, Noordijk EM.  et al.  Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery.  Ann Neurol. 1993;33:583-5908498838Google ScholarCrossref
Original Contribution
June 7, 2006

Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Departments of Radiology (Drs Aoyama, Shirato, and Katoh) and Global Health and Epidemiology, Division of Preventive Medicine (Dr Kobashi), Hokkaido University Graduate School of Medicine, Sapporo, Japan; Department of Radiology, University of Tokyo Hospital, Tokyo, Japan (Drs Tago and Nakagawa); Department of Radiology, Kanto Medical Center NTT EC, Tokyo, Japan (Dr Toyoda); Department of Radiology, Chiba Cancer Center, Chiba, Japan (Dr Hatano); Department of Radiology, Hiroshima University School of Medicine, Hiroshima, Japan (Dr Kenjyo); Department of Radiology, Kyoto University School of Medicine, Kyoto, Japan (Dr Oya); Department of Radiology, Hyogo Medical Center for Adults, Akashi, Japan (Dr Hirota); Department of Radiology, Izumisano General Hospital, Izumisano, Japan (Dr Shioura); Department of Radiology, Keio University School of Medicine, Tokyo, Japan (Dr Kunieda); Department of Radiology, Osaka Medical College, Osaka, Japan (Dr Inomata); Department of Radiology, Kitazato Medical School, Sagamihara, Japan (Dr Hayakawa).

JAMA. 2006;295(21):2483-2491. doi:10.1001/jama.295.21.2483

Context In patients with brain metastases, it is unclear whether adding up-front whole-brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) has beneficial effects on mortality or neurologic function compared with SRS alone.

Objective To determine if WBRT combined with SRS results in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death.

Design, Setting, and Patients Randomized controlled trial of 132 patients with 1 to 4 brain metastases, each less than 3 cm in diameter, enrolled at 11 hospitals in Japan between October 1999 and December 2003.

Interventions Patients were randomly assigned to receive WBRT plus SRS (65 patients) or SRS alone (67 patients).

Main Outcome Measures The primary end point was overall survival; secondary end points were brain tumor recurrence, salvage brain treatment, functional preservation, toxic effects of radiation, and cause of death.

Results The median survival time and the 1-year actuarial survival rate were 7.5 months and 38.5% (95% confidence interval, 26.7%-50.3%) in the WBRT + SRS group and 8.0 months and 28.4% (95% confidence interval, 17.6%-39.2%) for SRS alone (P = .42). The 12-month brain tumor recurrence rate was 46.8% in the WBRT + SRS group and 76.4% for SRS alone group (P<.001). Salvage brain treatment was less frequently required in the WBRT + SRS group (n = 10) than with SRS alone (n = 29) (P<.001). Death was attributed to neurologic causes in 22.8% of patients in the WBRT + SRS group and in 19.3% of those treated with SRS alone (P = .64). There were no significant differences in systemic and neurologic functional preservation and toxic effects of radiation.

Conclusions Compared with SRS alone, the use of WBRT plus SRS did not improve survival for patients with 1 to 4 brain metastases, but intracranial relapse occurred considerably more frequently in those who did not receive WBRT. Consequently, salvage treatment is frequently required when up-front WBRT is not used.

Trial Registration Identifier: C000000412